PEGylated liposomal doxorubicin: present and future role in the treatment of ovarian cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J. Clin. Oncol.21, S149–S167, (2003).
   PubMedGoogle Scholar
• Ozols RF: Update on the management of ovarian cancer. Cancer J.8(Suppl. 1), S22–S30, (2002).
   PubMed Web of Science ®Google Scholar
• Markman M, Reichman B, Hakes T et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol.9, 1801–1805, (1991).
   PubMed Web of Science ®Google Scholar
• Campos SM, Penson RT, Mays AR et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol.81, 206–212 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol.18, 3093–3100 (2000).
   PubMed Web of Science ®Google Scholar
• Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsutlation. J. Clin. Oncol.15, 987–993 (1997).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of PEGylated liposomal doxorubicin versus topotecan. J. Clin. Oncol.19, 3312–3322 (2001).
   PubMed Web of Science ®Google Scholar
• Siu L, Moore M. Pharmacology of anticancer drugs. In: The Basic Science of Oncology (4th Edition). Tannock I, Hill R, Bristow R et al. (Eds). McGraw-Hill, New York, NY, USA, 322–348 (2005).
   Google Scholar
• Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res.16, 175–183 (2006).
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Barenholz Y, Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res.10, 703–708 (1993).
   PubMed Web of Science ®Google Scholar
• Rahman A, Treat J, Roh JK et al. A Phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J. Clin. Oncol.8, 1093–1100 (1990).
   PubMed Web of Science ®Google Scholar
• Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol.13, 1777–1785 (1995).
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res.52, 891–896 (1992).
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res.54, 987–992 (1994).
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with PEGylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol.95, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrandina G, Lorusso D, Pignata S et al. Proceedings of: 2007 ASCO Annual Meeting. A randomized Phase III study of gemcitabine (GEM) versus PEGylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC). J. Clin. Oncol.25(Suppl. 18), (2007) (Abstract 5506).
   Google Scholar
• Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with PEGylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol.25, 2811–2818 (2007).
   PubMed Web of Science ®Google Scholar
• Rose PG. PEGylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist10, 205–214 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with PEGylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase II trial. Ann. Oncol.18, 263–268 (2007).
   PubMed Web of Science ®Google Scholar
• Stuart G, Oza A, Provencher D et al. Efficacy of PEGylated liposomal doxorubicin (PLD) plus carboplatin in patients with intermediate sensitive relapsing advanced ovarian cancer. Eur. J. Cancer3, 272 (2005).
   Google Scholar
• Hilpert F, Loibl S, Huober J et al. Proceedings of: 2006 ASCO Annual Meeting. Combination therapy with PEGylated liposomal doxorubicin and carboplatin in malignant gynecologic tumors. A prospective multicenter Phase II trial of the AGO-OVAR and the AGO Kommission Uterus (AGO-K-Ut). J. Clin. Oncol.24(Suppl. 18) (2006) (Abstract 5095).
   PubMed Web of Science ®Google Scholar
• Vorobiof DA, Rapoport B, Slabber C et al. Proceedings of: 2004 ASCO Annual Meeting. Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer. J. Clin. Oncol.22(Suppl. 14) (2004) (Abstract 5091).
   Google Scholar
• Alberts DS, Liu PY, Wilczynski S et al. Phase III randomized trial of PEGylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy: Southwest Oncology Group Protocol S0200. J. Clin. Oncol.25 (2007) (Abstract 5551).
   Google Scholar
• Ferrandina G, Paris I, Ludovisi M et al. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. Gynecol. Oncol.98, 267–273 (2005).
   PubMed Web of Science ®Google Scholar
• Mirza MR, Lund B, Bertelsen K et al. PEGylated liposomal doxorubicin (PLD) and gemcitabine (GEM) in combination in the salvage treatment of epithelial ovarian cancer (OC) – a Danish Gynaecologic Cancer Group (DGC) study. J. Clin. Oncol.24 (2006) (Abstract 5094).
   Google Scholar
• Skarlos DV, Kalofonos HP, Fountzilas G et al. Gemcitabine plus PEGylated liposomal doxorubicin in patients with advanced epithelial ovarian Cancer Resistant/refractory to platinum and/or taxanes. A HeCOG Phase II study. Anticancer Res.25, 3103–3108 (2005).
   PubMed Web of Science ®Google Scholar
• Verhaar-Langereis M, Karakus A, van Eijkeren M et al. Phase II study of the combination of PEGylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int. J. Gynecol. Cancer16, 65–70 (2006).
   PubMed Web of Science ®Google Scholar
• Chinet-Charrot P, Joly F, Bourgeois H et al. Association of PEGylated liposomal doxorubicin (PLD) and ifosfamide (IFO) in early recurrent ovarian cancer patients: a multicenter Phase II trial. J. Clin. Oncol.23, 5043 (2005) (Meeting Abstracts).
   Google Scholar
• Pignata S, Scambia G, Savarese A et al. Safety of a 3-weekly schedule of carboplatin plus PEGylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer6, 202 (2006).
   PubMed Web of Science ®Google Scholar
• Potamianou A, Androulakis N, Papakotoulas P et al. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter Phase II trial. Oncology69, 348–353 (2005).
   Google Scholar
• Bookman MA; for the Gynecologic Cancer InterGroup through the Gynecologic Oncology G. GOG0182-ICON5: 5-arm Phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG–lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J. Clin. Oncol.24 (2006) (Abstract 5002).
   PubMed Web of Science ®Google Scholar
• DiSilvestro PA, Fisher M, Pearl ML et al. Pilot Phase 2 trial of 4 months of maintenance PEGylated liposomal doxorubicin in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy. Gynecol. Obstet. Invest.63, 1–6 (2007).
   PubMed Web of Science ®Google Scholar
• Rocconi RP, Straughn JM Jr, Leath CA III et al. PEGylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist11, 336–341 (2006).
   PubMed Web of Science ®Google Scholar
• Andreopoulou E, Gaiotti D, Kim E et al. PEGylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann. Oncol.18, 716–721 (2007).
   PubMed Web of Science ®Google Scholar
• Uyar D, Kulp B, Peterson G et al. Cardiac safety profile of prolonged (>or=6 cycles) PEGylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol. Oncol.94, 147–51 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Tajuddin A, Guitart J et al. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer75, 2169–73 (1995).
   PubMed Web of Science ®Google Scholar
• Lopez AM, Wallace L, Dorr RT et al. Topical DMSO treatment for PEGylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother. Pharmacol.44, 303–6 (1999).
   PubMed Web of Science ®Google Scholar
• Lorusso D, Di Stefano A, Carone V et al. PEGylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann. Oncol.18, 1159–1164 (2007).
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P et al. Randomized Phase III study of PEGylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol.25, 3892–3901 (2007).
   PubMed Web of Science ®Google Scholar
• Rose PG, Maxson JH, Fusco N et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol. Oncol.82, 323–328 (2001).
   PubMed Web of Science ®Google Scholar
• Lorusso D, Naldini A, Testa A et al. Phase II study of PEGylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology67, 243–249 (2004).
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K et al. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol.78, 369–372 (2000).
   PubMed Web of Science ®Google Scholar
• Sehouli J, Oskay-Ozcelik G, Kuhne J et al. Biweekly PEGylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann. Oncol.17, 957–961 (2006).
   PubMed Web of Science ®Google Scholar
• Nicoletto MO, Falci C, Pianalto D et al. Phase II study of PEGylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol. Oncol.100, 318–323 (2006).
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol.15, 2183–2193 (1997).
   PubMed Web of Science ®Google Scholar